Abstract
Laboratory analysis for genetic susceptibility to cancer is a rapidly evolving discipline. This chapter will provide a brief overview to the types of clinical laboratory tests that are currently being performed for characterization of mutational status in cancer susceptibility genes. The latter portion will focus on comprehensive sequencing of the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 as a representative model of predispositional testing for inherited cancer and to demonstrate the complexity of current diagnostic tests.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aitkin M, Anderson D, Francis B, Hinde J: Statistical modelling in glim. Walton Street,Oxford, England OX2 6DP: Oxford University Press, 1989
Beaudet AL, Tsui LC: A suggested nomenclature for designating mutations. Hum Mut 2:245–248, 1993
Berchuck A, Cirisano F, Lancaster JM, et al: Role of BRCA1 mutation screening in the management of familial ovarian cancer. American Journal of Obstetrics & Gynecology 175:738–746, 1996
Breast cancer facts, and figures 1996. Atlanta: American Cancer Society, 1995:3
Breast Cancer Information Core. http://www.nhgri.nih.gov/ Intramural_research/Lab_transfer/BIC, 1997
Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1, and BRCA2. Cancer Genetics Studies Consortium. JAMA 277: 977–1003, 1997
Chapman MS, Verma IM: Transcriptional activation by BRCA1. Nature 382:678–679, 1996
Claus EB, Schildkraut JM, Thompson WD, et al: The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324, 1996
Cotton RGH: Mutation Detections, Oxford Univ. Press 1997
Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer [see comments]. New England Journal of Medicine 336:1409–1415, 1997
Cummings S, Olopade O: Predisposition Testing for Inherited Breast Cancer: Oncology, Vol.12, Number 8, Aug. 1998
Easton DF, Bishop DT, Ford D, et al: Genetic linkage analysis in familial breast, and ovarian cancer: results from 214 families. Am J Hum Genet 52:678–701, 1993
Easton DF, Ford D, Bishop DT, et al: Breast, and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56:265–271, 1995
Easton DF, Steele L, Fields P, et al: Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13ql2-13. Am J Hum Genet 61:120–128, 1997
Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695, 1994
Friedman LS, Ostermeyer EA, Szabo CI, et al: Confirmation of BRCA1 by analysis of germline mutations linked to breast, and ovarian cancer in ten families. Nature Genetics 8:399–404, 1994
Gayther SA, Warren W, Mazoyer S, et al: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genetics 11:428–433, 1995
Krainer M, Silva-Arrieta S, FitzGerald MG, et al: Differential contributions of BRCA1 and BRCA2 to earlyonset breast cancer. New England Journal of Medicine 336:1416–1421, 1997
Lindor NM, Greene MH, Mayo Familial Cancer Program: The Concise Handbook of Family Cancer Syndromes. Journal of the National Cancer Institute, Vol.90, NO.14, 1998
Mazoyer S, Dunning AM, Serova O, et al: A polymorphic stop codon in BRCA2. Nature Genetics 14:253–254, 1996
McCancer KL, Jorde LB: Evaluating the Genetic Risk of Breast Cancer: The Nurse Practitioner, Aug. 1998
Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71, 1994
Milner J, Ponder B, Hughes-Davies L, et al: Transcriptional activation functions in BRCA2. Nature 386:772–773, 1997
Narod SA, Ford D, Devilee P, et al: An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 56:254–264, 1995
NIH Consensus Development Panel on Ovarian Cancer: Ovarian Cancer. Screening, treatment, and followup. JAMA 273:491–497, 1995
Phelan CM, Lancaster JM, Tonin P, et al: Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genetics 13:120–122, 1996
Robson ME, Offit K: New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. Lancet 350:117–118, 1997
Scholl T, Pyne MT: High Throughput Automatic DNA Sequence Analysis of the Breast/Ovarian Cancer Susceptibility Genes BRCA1 and BRCA2, Personal Communication
Serova OM, Mazoyer S, Puget N, et al: Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 60:486–495, 1997
Shattuck-Eidens D, Oliphant A, McClure M, et al: BRCA1 sequence analysis in women at high risk for susceptibility mutations: risk factor analysis and implications for genetic testing. JAMA 278:1242–1250, 1997
Shen MR, Frank TF, Gumpper K, Deffenbaugh A, Ward BE: Novel mutations in BRCA1 and BRCA2 genes detected by automated high throughput sequencing. Am J Hum Genet 63
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 14:1730–1736, 1996
Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, et al: BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 60: 1021–1030, 1997
Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1, and BRCA2 among Ashkenazi Jews. New England Journal of Medicine 336:1401–1408, 1997
Tavtigian SV, Simard J, Rommens J, et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genetics 12:333–337, 1996
Tessaro I, Borstelmann N, Regan K, et al: Genetic testing for susceptibility to breast cancer: findings from women’s focus groups. Journal of Womens Health 6:317–327, 1997
Tonin P, Weber B, Offit K, et al: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nature Med 2:1179–1183, 1996
Vasen HFA, Mecklin J-P, Meera Khan P, et al: The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425, 1991
Ward BE, Manley S, McClure M, et al: Clinical diagnostic laboratory experience with BRCA1 and BRCA2 utilizing DNA sequencing technology. Am J Hum Genet: 61
Wijnen J, Meera Khan P, Vasen H, et al: Hereditary non-polyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. Am J Hum Genet 61:329–335, 1997
Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792, 1995
Wu LC, Wang ZW, Tsan JT, et al: Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nature Genetics 14:430–440, 1996
Yancik R: Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71:517–523, 1993
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ward, B.E. (1999). The Laboratory Analysis of Cancer Susceptibility Genes. In: Shaw, G.L. (eds) Cancer Genetics for the Clinician. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4699-3_7
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4699-3_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7128-1
Online ISBN: 978-1-4615-4699-3
eBook Packages: Springer Book Archive